Interplay of Drug Metabolism and Transport: A Real Phenomenon or an Artifact of the Site of Measurement?
- 3 November 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 6 (6) , 1756-1765
Abstract
The interdependence of both transport and metabolism on the disposition of drugs has recently gained heightened attention in the literature, and has been termed the “interplay of transport and metabolism”. Such “interplay” is observed when inhibition of biliary clearance of a drug results in an “apparent” increase in the metabolic clearance of the drug or vice versa. In this manuscript, we derived and explored through simulations a physiological-based pharmacokinetic model that integrates both transport and metabolism and explains the “apparent” dependence of hepatic clearance on both these processes. In addition, we show that the phenomenon of hepatic “transport−metabolism interplay” is a result of using the plasma concentration as a point of reference when calculating metabolic or biliary clearance, and this interplay is maximal when the drug is actively transported into the hepatocytes (i.e., hepatocyte sinusoidal influx clearance is greater than the sinusoidal efflux clearance). When the hepatic drug concentration is used as a reference point to calculate metabolic or biliary clearance, this interplay ceases to exist. A mechanistic understanding of this interplay phenomenon can be used to explain the somewhat paradoxical results that may be observed in drug−drug interaction studies when a drug is cleared by both metabolism and biliary excretion. That is, when one of these two pathways is inhibited, the other pathway appears to be induced or activated. This interplay results in an increase in hepatic drug concentrations and therefore has implications for the hepatic efficacy and toxicity of a drug.Keywords
This publication has 24 references indexed in Scilit:
- Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humansNaunyn-Schmiedeberg's Archives of Pharmacology, 2008
- Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugsExpert Opinion on Drug Metabolism & Toxicology, 2008
- Coordinated induction of drug transporters and phase I and II metabolism in human liver slicesEuropean Journal of Pharmaceutical Sciences, 2008
- Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptakeXenobiotica, 2007
- Prediction of Intestinal First-Pass Drug MetabolismCurrent Drug Metabolism, 2007
- Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor PathwaysDrug Metabolism and Disposition, 2007
- Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test ResultsClinical Pharmacology & Therapeutics, 2007
- Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functionsPharmacology & Therapeutics, 2006
- MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotypeClinical Pharmacology & Therapeutics, 2006
- In Vivo Effects of Cyclosporin A and Ketoconazole on the Pharmacokinetics of Representative Substrates for P-Glycoprotein and Cytochrome P450 (CYP) 3A in RatsBiological and Pharmaceutical Bulletin, 2005